Compass Pathways Q1 net loss $35.2M ($0.55/share); phase 3 TRD on track; PTSD phase 2 positive

COMPASS Pathways plc

2024-Q1 EPS reported -$0.55

Net loss $35.2M vs $24.2M in Q1 2023; EPS loss $0.55 vs $0.57.
Cash $262.9M at March 31, 2024, up from $220.2M; net $63.5M raised via ATM and warrants.
COMP360 phase 3 for TRD on track: COMP005 top-line Q4 2024, COMP006 mid-2025.
Phase 2 PTSD open-label: 25mg single dose well tolerated; CAPS-5 reduction 29.9 pts at week 4.
Michael Gold joins as Chief R&D Officer May 20; Trevor Mill departs as Chief Development Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COMPASS Pathways plc reported three months ended March 31, 2024 results: net income $35.2 million, EPS $0.55 loss per share. Guidance initiated.

Period: three months ended March 31, 2024
Net income: $35.2 million
EPS: $0.55 loss per share
Guidance: initiated
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2024, was $35.2 million, or $0.55 loss per share (including non-cash share-based compensation expense of $5.1 million), compared with $24.2 million, or $0.57 loss per share, during the same period in 2023 (including non-cash-share-based compensation expense of $4.1 million).

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

COMPASS Pathways plc filing history →

Source: SEC EDGAR

accession 0001628280-24-021352

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.